Trecondi 1 g powder for solution for infusion

DRUG4 trials

Sponsors

Assistance Publique Hopitaux De Paris, Fondazione Santobono Pausilipon Onlus, Fondazione Telethon Ets, San Raffaele Hospital, Ospedale Pediatrico Bambino Gesu

Conditions

Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 geneEwing SarcomaFramework for OptimizingMyelofibrosisRefiningand Unifying Management of HSCT in Pediatric ALL

Phase 1

A phase I/II open label study to assess safety, feasibility and efficacy of ex vivo expanded, autologous haematopoietic stem and progenitor cell populations that contain CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA in children with autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene.

Not yet recruitingCTIS2024-518972-30-00

Fondazione Telethon Ets, San Raffaele HospitalAutosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

Target: 8Updated: 2025-08-06

Phase 2

FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis : A phase 2 prospective multicentric prospective study

Active, not recruitingCTIS2024-513325-23-00

Assistance Publique Hopitaux De ParisMyelofibrosis

Start: 2021-02-03Target: 28Updated: 2024-07-23

Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma.

Not yet recruitingCTIS2024-518912-37-01

Fondazione Santobono Pausilipon OnlusEwing Sarcoma

Target: 60Updated: 2024-12-09

Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.

RecruitingCTIS2025-522052-13-00

Ospedale Pediatrico Bambino Gesuand Unifying Management of HSCT in Pediatric ALL, Framework for Optimizing, Refining

Start: 2025-12-24Target: 735Updated: 2025-11-24